Glz XR Tablet contains Gliclazide 60mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. This extended-release formulation provides a sustained glucose-lowering effect by stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby improving glycemic control. Glz XR Tablet is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise, to achieve optimal blood glucose levels and reduce the risk of diabetes-related complications. The extended-release mechanism allows for once-daily dosing, enhancing patient compliance and maintaining steady plasma drug concentrations. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to sulfonylureas. Common side effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Regular monitoring of blood glucose levels and periodic assessment of renal and hepatic function are recommended during therapy. Dose adjustments may be necessary based on glycemic response and tolerability. Glz XR Tablet should be used cautiously in elderly patients and those with concurrent medical conditions. Patients are advised to adhere strictly to prescribed dosages and report any adverse effects to their healthcare provider promptly.